



## AGTC to Present at the 2021 Wells Fargo Virtual Healthcare Conference

September 2, 2021

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that management will be participating in a fireside chat at the 2021 Wells Fargo Virtual Healthcare Conference on September 10<sup>th</sup>, 2021 at 8:40am E.T.

Audio webcasts of the presentation can be accessed by visiting <http://ir.agtc.com/eventsand-presentations>. A replay will be available on the Company's website following the events.

### About AGTC

AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. AGTC's most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM B3 and ACHM A3). Its preclinical programs build on the Company's industry leading AAV manufacturing technology and scientific expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders. In recent years AGTC has entered into strategic partnerships with companies including Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for neurology, and Bionic Sight, LLC, an innovator in the emerging field of optogenetics and retinal coding.

### IR CONTACT:

Jonathan Nugent  
Stern IR  
T: 212-698-8698  
[Jonathan.nugent@sternir.com](mailto:Jonathan.nugent@sternir.com)

### Corporate Contacts:

Stephen Potter  
Chief Business Officer  
Applied Genetic Technologies Corporation  
T: (617) 413-2754  
[spotter@agtc.com](mailto:spotter@agtc.com)



Source: Applied Genetic Technologies Corporation